Skip to content
10-Q

Quarterly Report

TANDEM DIABETES CARE INC TNDM

0001438133-26-000049

← back to feed
Filed
May 7, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 4, 2026 68.53M sh
Shares Diluted Q1 2026 · Mar 31, 2026 68.4M sh
Shares Diluted Q1 2026 · Mar 31, 2025 66.4M sh
Capex Q1 2026 · Mar 31, 2026 $6.27M
Capex Q1 2026 · Mar 31, 2025 $2.97M
Operating Cash Flow Q1 2026 · Mar 31, 2026 $11.05M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$18.28M
Long Term Debt Q1 2026 · Mar 31, 2026 $601.77M
Long Term Debt Q1 2026 · Dec 31, 2025 $310.04M
Short Term Investments Q1 2026 · Mar 31, 2026 $390.93M
Short Term Investments Q1 2026 · Dec 31, 2025 $202.03M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $179.33M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $90.63M
Stockholders Equity Q1 2026 · Mar 31, 2026 $132.4M
Stockholders Equity Q1 2026 · Dec 31, 2025 $155.17M
Stockholders Equity Q1 2026 · Mar 31, 2025 $155.29M
Stockholders Equity Q1 2026 · Dec 31, 2024 $263.1M
Current Liabilities Q1 2026 · Mar 31, 2026 $247.96M
Current Liabilities Q1 2026 · Dec 31, 2025 $242.72M
Total Liabilities Q1 2026 · Mar 31, 2026 $1.02B
Total Liabilities Q1 2026 · Dec 31, 2025 $725.94M
Current Assets Q1 2026 · Mar 31, 2026 $887.1M
Current Assets Q1 2026 · Dec 31, 2025 $618.14M
Total Assets Q1 2026 · Mar 31, 2026 $1.15B
Total Assets Q1 2026 · Dec 31, 2025 $881.11M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.30
Eps Diluted Q1 2026 · Mar 31, 2025 −$1.97
Eps Basic Q1 2026 · Mar 31, 2026 −$0.30
Eps Basic Q1 2026 · Mar 31, 2025 −$1.97
Sga Expense Q1 2026 · Mar 31, 2026 $108.19M
Sga Expense Q1 2026 · Mar 31, 2025 $113.85M
Net Income Q1 2026 · Mar 31, 2026 −$20.39M
Net Income Q1 2026 · Mar 31, 2025 −$130.56M
Operating Income Q1 2026 · Mar 31, 2026 −$17.43M
Operating Income Q1 2026 · Mar 31, 2025 −$120.88M
Gross Profit Q1 2026 · Mar 31, 2026 $136.79M
Gross Profit Q1 2026 · Mar 31, 2025 $118.41M
Cost Of Revenue Q1 2026 · Mar 31, 2026 $110.43M
Cost Of Revenue Q1 2026 · Mar 31, 2025 $116.02M
Revenue Q1 2026 · Mar 31, 2026 $247.22M
Revenue Q1 2026 · Mar 31, 2025 $234.42M